Justin Wagnon, NP
Adult Health · Cordele, GANPI 1295112183
Payments from drug & device makers
Across 141 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$432
- AbbVie$328
- AstraZeneca$327
- Sunovion Pharmaceuticals Inc.$256
- Boston Scientific$231
- Novartis$206
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,22998%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 19 | $432 |
| AbbVie | 21 | $328 |
| AstraZeneca | 7 | $327 |
| Sunovion Pharmaceuticals Inc. | 16 | $256 |
| Boston Scientific | 3 | $231 |
| Novartis | 10 | $206 |
| Novo Nordisk | 8 | $176 |
| Sumitomo Pharma America, Inc. | 8 | $148 |
| Medtronic | 2 | $122 |
| Amgen | 2 | $117 |
| Xeris Pharmaceuticals, Inc. | 6 | $116 |
| Paratek Pharmaceuticals, Inc. | 6 | $112 |
| Astellas Pharma US Inc | 3 | $100 |
| Abiomed | 1 | $90 |
| Pfizer | 4 | $61 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Bayer | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| GSK | 2 | $35 |
| Vifor Pharma, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| UCB, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$249
- GENERAL PAIN MANAGEMENT$195
- Repatha$100
How this compares
$3,294 in reported general payments places this provider in the 85th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $171,417 |
| FarxigaDapagliflozin Propanediol | 183 | $156,897 |
| EliquisApixaban | 305 | $143,741 |
| RybelsusSemaglutide | 60 | $105,074 |
| LinzessLinaclotide | 103 | $93,673 |
| MounjaroTirzepatide | 50 | $57,594 |
| JanuviaSitagliptin Phosphate | 60 | $51,156 |
| EntrestoSacubitril/Valsartan | 43 | $39,361 |
| JardianceEmpagliflozin | 28 | $38,735 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $37,330 |
| VraylarCariprazine Hcl | 21 | $33,077 |
| MyrbetriqMirabegron | 63 | $27,174 |
| GemtesaVibegron | 32 | $26,261 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 48 | $24,614 |
| ZenpepLipase/Protease/Amylase | 13 | $22,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $176 | $276,491203 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $327 | $168,507214 claims |
| AbbVieLinzess, Vraylar, Ubrelvy, Creon | $328 | $150,394150 claims |
| PfizerEliquis | $61 | $143,741305 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $35 | $59,449129 claims |
| MerckJanuvia | $20 | $51,15660 claims |
| NovartisEntresto | $206 | $39,36143 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $27,17463 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $148 | $26,26132 claims |
| Sanofi-aventis U.S. LLCLantus | $39 | $3,06029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 577 adult health providers in Georgia.
Other adult health in Cordele
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.